All In Biotech

Drug Trial Radar · NCT03905603

Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS

Last checked: Nov 20, 2026Latest source record: Nov 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

144

Planned (sponsor's estimate)

Start

Oct 8, 2019

Primary completion

Apr 1, 2026

Study completion May 1, 2026

Sponsor

Lead sponsor
University of VirginiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Female only, from 20 years, up to 49 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The objective of the study is to determine the relative contributions of four established predictors of hyperandrogenism (luteinizing hormone \[LH\] secretion, ovarian response to recombinant human chorionic gonadotropin \[r-hCG\] administration, adrenal response to adrenocorticotropic hormone \[ACTH\] administration, and hyperinsulinemia) in older vs. young women with Polycystic Ovary Syndrome (PCOS) in a cross-sectional, physiological study. The investigators hypothesize that hyperinsulinemia is a stronger independent predictor of free testosterone (T) in older reproductive aged (vs. young) women with PCOS.

Conditions

  • Polycystic Ovary Syndrome

Interventions

  • ACTHDrug

    ACTH (Cosyntropin) 250 mcg will be given once during the study.

  • rhCGDrug

    rhCG (Ovidrel) 250 mcg will be given once during the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in calculated free testosterone concentrationsTime frame: baseline, 30 mininutes and 1 hour after adrenocorticotropic hormone (ACTH), 24 hours after recombinant human chorionic gonadotropin (rhCG).
  2. Mean luteinizing hormone (LH) concentrationsTime frame: overnight frequent blood sampling (every 10 mininutes for 12 hours)
  3. Change in ovarian 17-hydroxyprogesterone to r-hCGTime frame: baseline, and 24 hours after receiving rhCG
  4. Change in adrenal 17-hydroxyprogesterone to ACTHTime frame: baseline, 30 minutes, and 60 minutes after ACTH
  5. Mean insulin level during oral glucose tolerance testTime frame: during 2 hours of oral glucose tolerance test

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Virginia

    Charlottesville, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.